Artificial intelligence enables comprehensive genome interpretation and nomination of candidate diagnoses for rare genetic diseases.
De La Vega Francisco M et al. Genome medicine 2021 10 (1) 153
Clinical interpretation of genetic variants in the context of the patient's phenotype is becoming the largest component of cost and time expenditure for genome-based diagnosis of rare genetic diseases. Artificial intelligence (AI) holds promise to greatly simplify and speed genome interpretation by integrating predictive methods with the growing knowledge of genetic disease. Here we assess the diagnostic performance of Fabric GEM, a new, AI-based, clinical decision support tool for expediting genome interpretation.
Application of full-genome analysis to diagnose rare monogenic disorders
AT Shieh et al, NPJ Genomic Medicine, September 23, 2021
We built a variant prioritization pipeline and tested FGA’s utility for diagnosis of rare diseases in a clinical setting. FGA identified structural variants and small variants with an overall diagnostic yield of 40% (20 of 50 cases) and 35% in exome-negative cases (8 of 23 cases), 4 of these were structural variants. FGA detected and mapped structural variants that are missed by short reads, including non-coding duplication, and phased variants across long distances of more than 180?kb. With the prioritization algorithm, longer DNA technologies could replace multiple tests for monogenic disorders and expand the range of variants detected.
Muscular dystrophies are a group of genetic disorders that result in muscle weakness over time. Each type of muscular dystrophy is different from the others. It is important to get help as early as possible. Muscular dystrophy has no cure, but acting early may help an individual with muscular dystrophy get the services and treatments he or she needs to lead a full life.
Myotonic Dystrophy at a Glance
Myotonic Dystrophy Foundation, September 15,2021
Myotonic dystrophy is a rare, multi-systemic, inherited disease that affects an estimated 1 in 2,100 people, or over 3.6 million individuals across the world. International Myotonic Dystrophy Awareness Day aims to garner the attention of the wider general public, policy makers, regulators, biopharmaceutical representatives, researchers, health care professionals, and anyone with an interest in changing the future of myotonic dystrophy.
News and Publications
A deep learning ensemble approach to prioritize candidate drugs against novel coronavirus 2019-nCoV/SARS-CoV-2.
K Deepthi, et al. Applied soft computing 2021 0 0. 107945
Architecture and organization of a Platform for diagnostics, therapy and post-covid complications using AI and mobile monitoring.
Hajder Miroslaw, et al. Procedia computer science 2021 0 0. 3711-3721
Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan.
Furukawa Koichi, et al. Open forum infectious diseases 2021 0 0. (10) ofab430
Haemolytic anemia triggered by SARS-CoV-2 in patient with hereditary spherocytosis.
Barberá-Pérez Paula María, et al. Medicina clinica (English ed.) 2021 0 0.
Identification of Unique Peptides for SARS-CoV-2 Diagnostics and Vaccine Development by an In Silico Proteomics Approach.
Kesarwani Veerbhan, et al. Frontiers in immunology 2021 0 0. 725240
Mesenchymal stem cells and COVID-19: What they do and what they can do.
Abu-El-Rub Ejlal, et al. World journal of stem cells 2021 0 0. (9) 1318-1337
Microsecond molecular dynamics suggest that a non-synonymous mutation, frequently observed in patients with mild symptoms in Tokyo, alters dynamics of the SARS-CoV-2 main protease.
Kuroda Daisuke, et al. Biophysics and physicobiology 2021 0 0. 215-222
Multiplex Biosensing for Simultaneous Detection of Mutations in SARS-CoV-2.
Xi Hui, et al. ACS omega 2021 0 0. (40) 25846-25859
N-terminal domain mutations of the spike protein are structurally implicated in epitope recognition in emerging SARS-CoV-2 strains.
Klinakis Apostolos, et al. Computational and structural biotechnology journal 2021 0 0.
Peptides Derived From S and N Proteins of Severe Acute Respiratory Syndrome Coronavirus 2 Induce T Cell Responses: A Proof of Concept for T Cell Vaccines.
Lee Yu-Sun, et al. Frontiers in microbiology 2021 0 0. 732450
SARS-CoV-2 nucleocapsid protein forms condensates with viral genomic RNA.
Jack Amanda, et al. PLoS biology 2021 0 0. (10) e3001425
SCovid: single-cell atlases for exposing molecular characteristics of COVID-19 across 10 human tissues.
Qi Changlu, et al. Nucleic acids research 2021 0 0.
Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody.
Yue Shuai, et al. Frontiers in immunology 2021 0 0. 751584
Suggestion of active 3-chymotrypsin like protease (3CL) inhibitors as potential anti-SARS-CoV-2 agents using predictive QSAR model based on the combination of ALASSO with an ANN model.
Mozafari Z, et al. SAR and QSAR in environmental research 2021 0 0. 1-26
[SARS-CoV-2 (COVID-19) in Patients with some Degree of Immunosuppression].
Cajamarca-Baron Jairo, et al. Reumatologia clinica 2021 0 0. (7) 408-419
MBL deficiency-causing B allele (rs1800450) as a risk factor for severe COVID-19.
Speletas Matthaios, et al. Immunobiology 2021 0 0. (6) 152136
Screening S protein - ACE2 blockers from natural products: Strategies and advances in the discovery of potential inhibitors of COVID-19.
Ma Le-le, et al. European journal of medicinal chemistry 2021 0 0. 113857
The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications.
Ivanisenko Nikita V, et al. Cell death discovery 2021 0 0. (1) 101
Airborne microplastics and SARS-CoV-2 in total suspended particles in the area surrounding the largest medical centre in Latin America.
Amato-Lourenço Luís Fernando, et al. Environmental pollution (Barking, Essex : 1987) 2021 0 0. (Pt A) 118299
A smartphone-based visual biosensor for CRISPR-Cas powered SARS-CoV-2 diagnostics.
Ma Long, et al. Biosensors & bioelectronics 2021 0 0. 113646